All In Biotech

Free tool

FAERS Monitor: Komzifti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220305 or its brand name (Komzifti, Ziftomenib). Reports on generic versions are filed under their own applications.

Reports

74

Serious

41

55% of reports

Hospitalization

14

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death18
  • pruritus9
  • off label use8
  • asthenia6
  • platelet count decreased5
  • product use in unapproved indication5
  • differentiation syndrome4
  • infection4
  • nausea4
  • drug ineffective3
  • fatigue3
  • pericarditis3
  • peripheral swelling3
  • pneumonia3
  • red blood cell count decreased3

Reports by year received

View as table
YearReports
20255
202669

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,085 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
pruritusSignal96.73.638
deathSignal185.94.072
product use in unapproved indicationSignal55.72.515
astheniaSignal64.52.113
pneumonia32.60.92
off label useSignal82.61.37
nausea41.40.60
fatigue31.10.40
drug ineffective30.60.20
platelet count decreased50.00.01,152,284
differentiation syndrome40.00.0871,325
infection40.00.0871,325
pericarditis30.00.0592,738
peripheral swelling30.00.0592,738
red blood cell count decreased30.00.0592,738

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.